Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 373 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Jonsson Comprehensive Cancer Center Clear all
Recruiting Phase 2 Interventional

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

NCT07323641
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Survey Administration, Telisotuzumab Vedotin
Procedure · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

Dentures and Dental Implants in Treating Patients Undergoing Surgery for Mouth Cancer

NCT00006341
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Implant
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
35 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Jun 7, 2026, 1:56 AM EDT
Terminated Early Phase 1 Interventional

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

NCT04777708
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma
Interventions
Nanoplexed Poly I:C BO-112, Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Not applicable Interventional

Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways

NCT01051037
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Body Radiation, Radiofrequency Ablation
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Not applicable Interventional

Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors

NCT03953157
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Arthralgia, Postmenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Dietary Intervention, Exercise Intervention, Questionnaire Administration
Dietary Supplement · Behavioral · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

NCT00004865
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, fluorouracil, paclitaxel
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Camden, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2009 · Synced Jun 7, 2026, 1:56 AM EDT
Recruiting Phase 2 Interventional

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

NCT04915508
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Hormone Therapy, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

NCT02775292
View directory record Official record
Conditions
Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Nivolumab, NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL, NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine, Positron Emission Tomography
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT00090909
View directory record Official record
Conditions
Lymphoma
Interventions
cisplatin, dexamethasone, gemcitabine hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 7, 2026, 1:56 AM EDT
Not listed Phase 2 Interventional

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

NCT00022321
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
gemtuzumab ozogamicin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Jun 7, 2026, 1:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictors of Patient Attitudes and Barriers to Skin Cancer Screening

NCT02235116
View directory record Official record
Conditions
Skin Cancer
Interventions
Survey
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Jun 7, 2026, 1:56 AM EDT
Withdrawn Phase 2 Interventional

BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

NCT00040989
View directory record Official record
Conditions
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
Interventions
BAY 56-3722, enzyme inhibitor therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Phase 1Phase 2 Interventional

Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer

NCT00006968
View directory record Official record
Conditions
Kidney Cancer
Interventions
filgrastim, cyclosporine, pentostatin, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Not applicable Interventional

Low-Fat Fish Oil Diet for Prostate Cancer Prevention

NCT00798876
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fish Oil, Vitamin E supplement, Western Diet, Low-Fat Diet, Medical Examination, Dietary Interview, Blood Draw, Radical Prostatectomy
Dietary Supplement · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jun 7, 2026, 1:56 AM EDT
Terminated Phase 1 Interventional

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

NCT04185311
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Ipilimumab, Nivolumab, Talimogene Laherparepvec
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Jun 7, 2026, 1:56 AM EDT
Terminated No phase listed Observational

18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

NCT02888301
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jun 7, 2026, 1:56 AM EDT
Completed No phase listed Observational

Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone

NCT00351728
View directory record Official record
Conditions
Ocular Melanoma, Choroidal Melanoma, Uveal Melanoma
Interventions
Not listed
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Jun 7, 2026, 1:56 AM EDT
Completed No phase listed Observational

Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients

NCT01051609
View directory record Official record
Conditions
Breast Cancer
Interventions
History and Physical Exam, Grip Strength Measurement, Surveys, Blood Collection, Ultrasound of Hand/Wrist
Other · Behavioral · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain

NCT00012116
View directory record Official record
Conditions
Metastatic Cancer
Interventions
temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jun 7, 2026, 1:56 AM EDT
Recruiting Not applicable Interventional

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

NCT04945642
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jun 7, 2026, 1:56 AM EDT
Active, not recruiting Phase 2 Interventional

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

NCT04395079
View directory record Official record
Conditions
Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Female Reproductive System Neoplasm
Interventions
Durvalumab, Internal Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 7, 2026, 1:56 AM EDT
Recruiting Early Phase 1 Interventional

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

NCT07235280
View directory record Official record
Conditions
Lung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Lung Cancer
Interventions
Biospecimen Collection, Computed Tomography Assisted Biopsy, Dapagliflozin Propanediol, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
22 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 7, 2026, 1:56 AM EDT
Active, not recruiting Not applicable Interventional

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT01345851
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy
Radiation · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 7, 2026, 1:56 AM EDT
Completed Not applicable Interventional

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

NCT02902757
View directory record Official record
Conditions
Glioblastoma
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 7, 2026, 1:56 AM EDT